Diopsys, a medical instrumentation company, has developed a new office-based Nova-Pattern electroretinography (PERG) test.
By utilizing visual evoked potential technology, the test measures the function of the inner retinal cells of the eye, especially in an area of the retina called the macula, which aids optometrists and ophthalmologists to diagnose and monitor vision disorders like glaucoma, macular degeneration and diabetic retinopathy.
Diopsys research director Alberto Gonzalez said the Diopsys NOVA-PERG is a new important addition to the company’s NOVA suite of tests.
"In one sitting, an eye care specialist can objectively measure the function of the patient’s retina while also measuring the function of the entire vision system, from the eye to the visual cortex," Gonzalez added.
"This will help doctors objectively distinguish between retinal and cortical pathway issues."
The company said it is also planning to launch the Nova-PERG test in 2012.